Completed PHASE2 INTERVENTIONAL 7-arm NCT02559921

Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.

Sponsor: Beijing Chaoyang District Centre for Disease Control and Prevention

Conditions Rabies

Interventions HRIG（20 IU/kg） HRIG（20 IU/kg） and vaccine placebo and vaccine rhRIG（20 IU/kg） rhRIG（20 IU/kg） and vaccine rhRIG（40 IU/kg） rhRIG（40 IU/kg） and vaccine

Updated 6 times since 2017 Last updated: Jan 19, 2016 Started: Dec 31, 2014 Primary completion: Aug 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rabies and is currently completed. Beijing Chaoyang District Centre for Disease Control and Prevention leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Chaoyang District Centre for Disease Control and Prevention

Data source: Beijing Chaoyang District Centre for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.